MOBIDIAG
Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.
These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The Amplidiag® RESP-4 assay can rapidly and simultaneously determine an accurate diagnosis from one patient sample using nasopharyngeal swabs, helping to guide clinicians to the relevant treatment decision for each patient. The test runs on the Mobidiag Amplidiag® Easy platform , which provides clinicians with an optimized sample screening process, with automated DNA/RNA extraction and PCR plate setup. Based on well-established high-throughput PCR technology, the platform can process 46 samples in approximately three hours.
This new test further broadens Mobidiag’s already available portfolio of diagnostics tests.
Tuomas Tenkanen, CEO of Mobidiag said, “We are very pleased to announce the CE-IVD marking for the Amplidiag® RESP-4 assay, which is highly relevant to both the traditional flu season and COVID-19. Symptoms caused by these viruses [SARS-CoV-2, Influenza A, Influenza B and RSV] can be very similar, and it is imperative that healthcare professionals are able to rapidly distinguish between them, in order to start the appropriate treatment for the benefit of patients.
In response to the growing need for fast and reliable diagnostics, at Mobidiag we are putting all our efforts into maintaining a high degree of autonomy in the production of our Amplidiag® tests by securing critical components to provide continuous support for our customers, as we all work together to control the spread of COVID-19.”
Mobidiag is currently developing Novodiag® RESP-4, a molecular diagnostic test using its Novodiag® platform for the rapid and on-demand detection of SARS-CoV-2, Influenza A, Influenza B and RSV. This test will complement Amplidiag® RESP-4 and enable clinicians to detect respiratory viruses to support early decisions in managing efficiently epidemiological and infection control measures, isolate patients in a timely manner, and ultimately improve patient care and outcomes.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you have any symptoms of respiratory infections.
Notes to editors
About Mobidiag Ltd
Mobidiag is a fast-growing molecular diagnostics company whose rapid, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210228005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duetti Secures $200 Million to Scale Independent Music Catalog Acquisitions and Enhance Platform Capabilities21.1.2026 14:01:00 CET | Press release
Funding Led by a $50 Million Series C Equity Investment from The Raine Group Duetti Inc. (“Duetti” or the “Company”), the music-tech and financial services company that empowers independent music creators to unlock the value of their music catalogs, today announces it has secured $200 million in new funding to accelerate music catalog acquisitions and expand its technology and services globally. The financing is led by a $50 million Series C equity investment by Raine Partners, the flagship growth equity fund of The Raine Group, alongside a second $125 million private securitization and a $25 million increase of an existing credit facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121033285/en/ In over three years, Duetti has raised over $635 million, including over $100 million in equity, to support the global independent music community. To date, the Company has partnered with more than 1,100 artists, songwriters,
Board Collaborates with Microsoft to Bring Agentic AI Into the Core of Enterprise Planning21.1.2026 14:00:00 CET | Press release
Domain-Specific, Enterprise-Ready AI Agents Support Continuous Planning Across Finance, Supply Chain and Merchandising Board, one of the leading Enterprise Planning Platforms, today announced the launch of Board Agents built on Microsoft Foundry. Board Agents deliver an intelligent suite of domain-specific, enterprise-ready AI agents that support real-world planning decisions across finance, supply chain, and merchandising. This marks the first Board enterprise planning capability developed with Microsoft Foundry, using Microsoft Azure’s agentic AI tools and services to accelerate secure, cloud-native AI innovation. The initial release includes FP&A and Controller Agents for the Office of Finance, with Merchandiser and Supply Chain Agents to follow. Board Agents are built natively into the Board Enterprise Planning Platform, providing a secure, governed foundation for applying agentic AI to high-impact planning use cases. “As interest in AI accelerates, many customers are looking for c
Copeland Advances AI and Digital Strategy with Acquisition of Bueno Analytics21.1.2026 13:00:00 CET | Press release
Acquisition integrates advanced SaaS capabilities to deliver smarter, data‑driven HVAC and cold chain solutions Copeland, a global provider of compression technologies and controls solutions, announced today that it has entered into an agreement to acquire Bueno Analytics (“Bueno”), an Australia-based company specializing in SaaS solutions that leverage embedded AI and machine learning to deliver building analytics, energy management and operational efficiency across commercial buildings and the cold chain. Bueno’s platform is deployed across several thousand customer sites worldwide, providing broad connectivity, full portfolio visibility and critical operational insights. Buildings account for an estimated 40% of global carbon emissions, with commercial buildings and the cold chain representing a significant share of that impact. The integration of Bueno’s platform with Copeland’s deep domain expertise will deliver a powerful suite of capabilities, including predictive maintenance, e
NIRSense, Inc. & Aspen Medical USA (AMUSA): Strengthening Frontline Medicine: U.S.–Developed Tissue Oxygenation Technology Delivered to Ukraine21.1.2026 13:00:00 CET | Press release
Today, NIRSense and Aspen Medical USA (AMUSA) are pleased to announce the donation of 12 portable tissue-ischemia monitoring kits (comprising advanced sensor consoles plus tablets) to the Ministry of Defence of Ukraine (MoD) for deployment in frontline Role-1 and Role-2 casualty care facilities in Ukraine. These investigational prototype systems are provided for use by military medical teams treating extremity-injured personnel (including those who have undergone tourniquet application) to assess and monitor tissue perfusion and oxygenation in real time. Why this matters In the battlefield context, timely recognition of compromised tissue perfusion (particularly in limbs subject to tourniquet use, major soft‐tissue injury or ischemia-reperfusion risk) can make the difference between viable salvage of the limb, avoidance of secondary complications, and optimal patient outcomes. The donated NIRSense kits, which will be administered by the Ukraine MoD under an approved protocol, may provi
Allshares Acquires U.S. Market Leader Stock & Option Solutions, Solidifying Its Position as a Global Leader in Equity Ownership Management21.1.2026 12:00:00 CET | Press release
Allshares, a global provider of equity ownership management software and services, today announced the acquisition of Stock & Option Solutions (“SOS” or the “Company”), a U.S.-based specialist in end-to-end equity compensation and plan administration. Stock & Option Solutions brings a track record of supporting the full life cycle of equity and compensation plan administration. Recognized as one of the Inc. 5000 fastest-growing companies in 2022, the Company has built a strong reputation for supporting organizations across the United States, from early-stage startups to large enterprises. Its platform-agnostic service model enables clients to optimize complex incentive structures across major equity technology systems. This acquisition marks a strategic milestone in Allshares’ expansion, establishing the U.S. as Allshares’ largest and fastest-growing market. By integrating SOS’ deep U.S. expertise, Allshares strengthens its ability to deliver seamless ownership management for clients o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom